Association between comorbid COPD or chronic bronchitis and the prognosis of patients with Dilated cardiomyopathy Authors: Guiting Zhou, Runjia Yu, Chuanjin Luo, Ping Li, Zhihua Huang, Bo Zhang, Guangjiao Liu, Yueqiao Zhong, Jiahua Liang Published: 2024 ABSTRACT AbstractAimsDilated cardiomyopathy (DCM) is characterized by unilateral or bilateral ventricular enlargement and reduced ventricular systolic function, with or without heart failure. In previous studies, we found that a history of chronic obstructive pulmonary disease (COPD) or chronic bronchitis is a high risk factor for DCM combined with pulmonary hypertension (PH). Therefore, we propose that the comorbidity of COPD or chronic bronchitis will increase the cardiogenic mortality of patients with DCM.MethodsData were collected from patients with DCM who were admitted to The First Affiliated Hospital of Guangzhou University of Chinese Medicine from October 2008 to April 2020. The primary endpoint was cardiac death. Multivariable Cox regression analyses were employed to assess the associations between the comorbidities COPD or chronic bronchitis with the study endpoints. Different adjusting models were used to adjust for potential confounders.ResultsA total of 305 DCM patients were ultimately enrolled, among whom 46 patients had COPD or chronic bronchitis. The median follow-up was 50 months. The rate of cardiac death in the COPD or chronic bronchitis group was significantly greater than that in the non-COPD or nonchronic bronchitis group (p < 0.001). The associations between comorbid COPD or chronic bronchitis and cardiac death remained robust after eliminating the possible effects of confounders. After grouping by PH, the risk difference was mainly derived from the intermediate- or high-probability PH group.ConclusionsComorbid COPD or chronic bronchitis increased the risk of cardiac death among DCM patients with an intermediate or high PH probability.Keywords: Dilated cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, chronic bronchitis, prognosis Introduction Dilated cardiomyopathy (DCM) is a nonischemic myocardial disease characterized by left ventricular or biventricular dilation and systolic dysfunction without pressure or volume overload or coronary artery disease [1,2]. Patients with DCM present with typical symptoms of systolic heart failure, but as the disease progresses, diastolic dysfunction follows [3]. DCM is a common cause of heart failure, arrhythmia, and sudden death and has a high mortality rate. The aetiology of DCM is complex. Studies have shown that the 5-year survival rate of patients with this disease is less than 50% after the initial diagnosis, and patients have a high mortality rate and poor prognosis [4]. The World Health Organization (WHO) estimated that approximately 5% of all deaths worldwide can be attributed to chronic obstructive pulmonary disease (COPD), which is likely to become the third major cause of death by 2030 [5]. Chronic bronchitis is considered a major component of COPD [6]. However, a study by Franke J et al. revealed that the prevalence of COPD in DCM patients was 36.4% [7]. COPD is a common comorbidity in heart failure patients and can exacerbate the clinical course of the disease, impacting treatment management. A concomitant diagnosis of COPD at the time of heart failure hospitalization increases the risk of subsequent hospitalization by almost 30% [8]. More importantly, related studies have shown that the longer the duration of DCM, the greater the possibility of pulmonary hypertension (PH) caused by a chronic increase in left atrial pressure. More than one-fifth of DCM patients have a high risk of PH [9]. According to previous studies, the incidence of cardiac death is markedly greater in patients with DCM and PH than in DCM patients without PH, with a hazard ratio of 11.79 [10,11]. In previous studies [12], we found that a history of COPD or chronic bronchitis is a high risk factor for DCM combined with PH. Therefore, we propose that the comorbidity of COPD or chronic bronchitis will increase the cardiogenic mortality of patients with DCM. Methods Patients Data were collected from patients with DCM who were admitted to The First Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangzhou, Guangdong Province of China) from October 2008 to April 2020. The inclusion criteria were as follows: (1) age > 18 years; (2) a clinical diagnosis of DCM; and (3) a detailed diagnostic work-up, including clinical evaluations, laboratory tests, electrocardiography, and echocardiography. Patients with significant coronary artery disease, primary heart valve disease, restrictive or obstructive cardiomyopathy, congenital heart disease, or severe arterial hypertension were excluded from the study. Echocardiographic assessments were performed on stable patients during outpatient visits or after stabilization in the case of urgent admission. All patients were in stable condition at the time of testing. Basic information and vital signs for each patient, such as sex, age, systolic blood pressure (BP), diastolic BP, and heart rate, were recorded. The presence of comorbidities, such as hypertension, diabetes mellitus, prior stroke, pulmonary infection, atrial fibrillation, and left bundle branch block (LBBB), was established by medical documentation or in-hospital diagnosis. DCM was defined by the presence of both an LVEF <50% and a dilated LV cavity in the absence of coronary artery stenosis >50% (as determined by coronary angiography), valvular heart disease, arterial hypertension, and secondary cardiac muscle disease attributable to any known systemic condition. The diagnosis of COPD was based on the clinical judgement of the investigator, taking into account the patient’s medical history, treatment and/or spirometric data [8]. The LVEF is an index of left ventricle contractility that indicates the degree of change in the left ventricle volume from diastole to systole. It is calculated by subtracting the end-systolic left ventricle volume from the end-diastolic left ventricle volume and dividing it by the end-diastolic left ventricle volume [13]. We defined chronic bronchitis as the presence of chronic cough and phlegm production that continued for 3 months for more than 2 consecutive years. All patients were followed from the date of their first assessment to the date of cardiac death or death from another cause. The death identification ICD-10 diagnosis codes I00–I09, I11, I13, or I20–I51 were assigned to cardiac death. Patients who died of unknown or other causes, as well as those who had received implanted cardiac resynchronization therapy (CRT) or an implantable cardioverter defibrillator (ICD), were excluded from the analysis. The study protocol complied with the Declaration of Helsinki. Prior to the study, the relevant institutional committees and the First Affiliated Hospital of Guangzhou University of Chinese Medicine Ethical Committee approved the study (protocol number: K[2020]135). Due to the retrospective and anonymous nature of the study, the First Affiliated Hospital of Guangzhou University of Chinese Medicine Ethical Committee waived the requirement for patient informed consent. PH probability The probability of PH was diagnosed in accordance with the 2015 European Society of Cardiology and the European Respiratory Society (ESC/ERS) Guidelines [14]. Briefly, patients were divided into low, intermediate, and high PH probability groups based on echocardiographic assessments at the tricuspid regurgitation peak velocity (TRV) in conjunction with the presence of echocardiographic signs from at least two different categories: (1) pulmonary artery (PA) signs, such as the PA diameter or acceleration time; (2) inferior vena cava (IVC) and right atrium (RA) signs, such as the diameter and inspiratory collapse of the IVC and the RA end-systolic area; and (3) ventricular signs. Statistical analysis Statistical analysis was performed using Stata 15.0 software. (We obtained a copyright licence from Stata 15.0 software.) The data are presented as numbers (percentages). Mann–Whitney U and chi-square (or Fisher’s exact) tests were used for comparisons between groups. Survival curves were constructed using the Kaplan–Meier method, and log-rank tests were used to compare differences between groups. Associations of comorbid COPD or chronic bronchitis with cardiac death were assessed using Cox regression models. We used five different models to adjust for potential confounders. p < 0.05 was considered to indicate statistical significance. Results Baseline characteristics A total of 305 DCM patients with 71 (23.28%) deaths were ultimately enrolled, among whom 46 patients (15.08%) had COPD or chronic bronchitis as a comorbidity. The characteristics and clinical management during hospitalization of the groups without COPD or chronic bronchitis and with COPD or chronic bronchitis are outlined in Tables 1 and 2. In general, the group of patients with COPD or chronic bronchitis as a comorbidity included more drinkers; those with lower levels of BNP, LVEDd and heart rate; and patients with a greater LVEF. Table 1.Comparison of baseline characteristics between patients with and without COPD or chronic bronchitis.CharacteristicsWithout COPD or chronic bronchitis (n = 259)With COPD or chronic bronchitis (n = 46) p Male182 (70.3)33 (71.7)0.840Age (years) ≤65192 (74.1)29 (63.0)0.121 >6567 (25.9)17 (37.0) Duration of DCM (years) <1161 (62.2)27 (58.7) 1–572 (27.8)10 (21.7)0.400 >526 (10.0)9 (19.6) Implemented heart failure therapy before hospitalization69 (26.6)14 (30.4)0.594Systolic BP (mmHg) <902 (0.8)1 (2.2) 90–129136 (52.5)21 (45.7)0.320 ≥130121 (46.7)24 (52.2) Diastolic BP (mmHg) <608 (3.1)2 (4.3) 60–7972 (27.8)19 (41.3)0.146 ≥80179 (69.1)25 (54.3) Heart rate (beats / min) <606 (2.3)3 (6.5) 60–99140 (54.1)31 (67.4)0.039 ≥100113 (43.6)12 (26.1) Ankle edema135 (52.1)18 (39.1)0.104Smoker90 (34.7)22 (47.8)0.090Drinker60 (23.2)18 (39.1)0.022Hypertension classification 1/2/3 (n)14/43/736/7/100.581Diabetes mellitus66 (25.5)13 (28.3)0.692Prior stroke16 (6.2)5 (10.9)0.400NYHA class 1/2/3/4 (n)8/79/103/691/15/16/140.820Pulmonary infection102 (39.4)14 (30.4)0.249Atrial fibrillation/Atrial flutter64 (24.7)14 (30.4)0.412LBBB31 (12.0)6 (13.0)0.837Notes: Data are presented as n (%). p < 0.05 is considered statistically significant. Abbreviations: COPD, Chronic obstructive pulmonary disease; BP, blood pressure; NYHA, New York Heart Association; LBBB, Left bundle branch block. Comparison of baseline characteristics between patients with and without COPD or chronic bronchitis. Notes: Data are presented as n (%). p < 0.05 is considered statistically significant. Abbreviations: COPD, Chronic obstructive pulmonary disease; BP, blood pressure; NYHA, New York Heart Association; LBBB, Left bundle branch block. Table 2.Clinical management during hospitalization.CharacteristicsWithout COPD or chronic bronchitis (n = 259)With COPD or chronic bronchitis (n = 46) p Hb (g/L)139 (125, 150)132 (114, 151)0.147 Normal224 (86.5)36 (78.3) Low35 (13.5)10 (21.7) PLT (109/L)201 (160, 249)196 (160, 254)0.848 <16064 (24.7)11 (23.9) 160–249132 (51.0)22 (47.8) >24963 (24.3)13 (28.3) Leukocyte (109/L)7.43 (6.04, 9.09)6.46 (5.73, 8.22)0.073 <5.9160 (23.2)16 (34.8) 5.91–8.96129 (49.8)24 (52.2) >8.9670 (27.0)6 (13.0) NEU (%)66.3 (58.5, 73.6)65.4 (58.4, 72.3)0.667 <58.564 (24.7)11 (23.9) 58.5–73.5130 (50.2)26 (56.5) >73.565 (25.1)9 (19.6) TC (mmol/L)4.07 (3.46, 4.74)4.12 (3.27, 4.74)0.612 <5.18217 (83.8)40 (87.0) 5.18–6.2132 (12.4)4 (8.7) >6.2110 (3.9)2 (4.3) TG (mmol/L)1.07 (0.82, 1.44)0.99 (0.79, 1.36)0.385 <1.70224 (86.5)38 (82.6) 1.70–2.2519 (7.3)1 (2.2) >2.2516 (6.2)7 (15.2) LDL-C (mmol/L)2.71 (2.10, 3.30)2.68 (2.11, 3.27)0.946 <3.37203 (78.4)36 (78.3) 3.37–4.1338 (14.7)8 (17.4) >4.1318 (6.9)2 (4.3) HDL-C (mmol/L)0.91 (0.74, 1.15)0.95 (0.75, 1.17)0.805 <1.04164 (63.3)30 (65.2) ≥1.0495 (36.7)16 (34.8) Fasting glucose (mg/dL)5.1 (4.5, 5.8)5.1 (4.7, 6.0)0.418 <3.917 (6.6)1 (2.2) 3.9–6.1197 (76.1)36 (78.3) >6.145 (17.4)9 (19.6) BNP (pg/mL)1623 (848, 2570)653 (346, 1831)<0.001 <66453 (20.5)23 (50.0) 664–2483136 (52.5)17 (37.0) >248370 (27.0)6 (13.0) Moderate/Severe TR129 (49.8)26 (56.5)0.401Moderate/Severe MR168 (64.9)31 (67.4)0.740LVEF (%)29 (22, 35)31 (25, 44)0.020 <2260 (23.2)5 (10.9) 22–36142 (54.8)25 (54.3) >3657 (22.0)16 (34.8) LVEDd (mm)65 (60, 72)65 (56, 69)0.013 <6058 (22.4)17 (37.0) 60–71133 (51.4)23 (50.0) >7168 (26.3)6 (13.0) TRV (m/s) 0.331 <2.9133 (51.4)20 (43.5) 2.9–3.455 (21.2)11 (23.9) >3.471 (27.4)15 (32.6) PH probability 0.261 Low97 (37.5)14 (30.4) Intermediate71 (27.4)12 (26.1) High91 (35.1)20 (43.5) Right ventricle diameter (mm) 0.730 <1959 (22.8)12 (26.1) 19–28151 (58.3)22 (47.8) >2849 (18.9)12 (26.1) Medication during hospitalization Beta-blocker209 (80.7)28 (60.9)0.003 Aldosterone receptor antagonist224 (86.5)39 (84.8)0.757 ACEI or ARB or ARNI234 (90.3)39 (84.8)0.382Notes: Data are presented as medians (interquartile range) and n (%). p < 0.05 is considered statistically significant. PLT, leukocyte, NEU, BNP, LVEF, LVEDd, and right ventricle diameter were separated into 3 groups according to Quartile. Abbreviations: COPD, Chronic obstructive pulmonary disease; Hb, Hemoglobin; PLT, Platelets; NEU, Neutrophil; TC, Total cholesterol; TG, Triglyceride; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; BNP, Brain natriuretic peptide; TR, Tricuspid regurgitation; MR, Mitral regurgitation; LVEF, Left ventricle ejection fraction; LVEDd, Left ventricle end-diastolic diameter; TRV, tricuspid regurgitation peak velocity; PH, pulmonary hypertension; ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, Angiotensin receptor neprilysin inhibitor. Clinical management during hospitalization. Notes: Data are presented as medians (interquartile range) and n (%). p < 0.05 is considered statistically significant. PLT, leukocyte, NEU, BNP, LVEF, LVEDd, and right ventricle diameter were separated into 3 groups according to Quartile. Abbreviations: COPD, Chronic obstructive pulmonary disease; Hb, Hemoglobin; PLT, Platelets; NEU, Neutrophil; TC, Total cholesterol; TG, Triglyceride; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; BNP, Brain natriuretic peptide; TR, Tricuspid regurgitation; MR, Mitral regurgitation; LVEF, Left ventricle ejection fraction; LVEDd, Left ventricle end-diastolic diameter; TRV, tricuspid regurgitation peak velocity; PH, pulmonary hypertension; ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, Angiotensin receptor neprilysin inhibitor. Associations between comorbid COPD or chronic bronchitis and clinical outcomes The median follow-up was 50 months (interquartile range 28–90 months). The rate of cardiac death in the COPD or chronic bronchitis group was significantly greater than that in the group without COPD or chronic bronchitis (41.3% vs. 20.1%, Table 3). The same result was found in the Kaplan–Meier analysis (Figure 1). We used multivariable Cox regression analysis to eliminate the possible effect of confounders. The results showed that the association remained significant after adjustment for the four different models (HR = 2.998, 95% CI = 1.505–5.974, adjusted by Model 4; the results of the other three models are presented in Table 4). Table 3.Comparison of clinical outcomes.CharacteristicsWithout COPD or chronic bronchitis (n = 259)With COPD or chronic bronchitis (n = 46) p Clinical outcomes Patients with cardiac death end points52 (20.1)19 (41.3)<0.001* Patients without cardiac death end points207 (79.9)27 (58.7) Notes: Data are presented as n (%). *Log-rank test. p < 0.05 is considered statistically significant. Abbreviation: COPD, Chronic obstructive pulmonary disease. Comparison of clinical outcomes. Notes: Data are presented as n (%). *Log-rank test. p < 0.05 is considered statistically significant. Abbreviation: COPD, Chronic obstructive pulmonary disease. Kaplan-Meier survival curve of the study population. ‘Number at risk’ represents the number of survivors. Table 4.Association between comorbid COPD or chronic bronchitis and prognosis.Cardiac deathGroupHazard ratio95% CI p UnadjustedWithout COPD or chronic bronchitisReference 0.001With COPD or chronic bronchitis2.5141.474–4.287 Adjusted; #1Without COPD or chronic bronchitisReference 0.001With COPD or chronic bronchitis2.4551.421–4.241 Adjusted; #2Without COPD or chronic bronchitisReference 0.006With COPD or chronic bronchitis2.2011.252–3.869 Adjusted; #3Without COPD or chronic bronchitisReference <0.001With COPD or chronic bronchitis2.9911.614–5.544 Adjusted; #4Without COPD or chronic bronchitisReference 0.002With COPD or chronic bronchitis2.9981.505–5.974 Notes: Associations of comorbid COPD or chronic bronchitis with cardiac death were analyzed using Cox regression models. The parameters shown in Table 1 and 2 for which p < 0.200 and the data of echocardiographic were subjected to multivariable cox regression. p < 0.05 is considered statistically significant. #1 -- Demographics (age, smoker, drinker). #2 -- #1 and admission presentation (Diastolic BP, heart rate, ankle edema). #3 -- #2 and serological indicators (Hb, leukocyte, BNP). #4 -- #3 and echocardiographic and medication (Moderate/Severe TR, Moderate/Severe MR, LVEF, LVEDd, Beta-blocker). Abbreviations: COPD, Chronic obstructive pulmonary disease; CI, confidence interval; BP, blood pressure; Hb, Hemoglobin; BNP, Brain natriuretic peptide; TR, Tricuspid regurgitation; MR, Mitral regurgitation; LVEF, Left ventricle ejection fraction; LVEDd, Left ventricle end-diastolic diameter. Association between comorbid COPD or chronic bronchitis and prognosis. Notes: Associations of comorbid COPD or chronic bronchitis with cardiac death were analyzed using Cox regression models. The parameters shown in Table 1 and 2 for which p < 0.200 and the data of echocardiographic were subjected to multivariable cox regression. p < 0.05 is considered statistically significant. #1 -- Demographics (age, smoker, drinker). #2 -- #1 and admission presentation (Diastolic BP, heart rate, ankle edema). #3 -- #2 and serological indicators (Hb, leukocyte, BNP). #4 -- #3 and echocardiographic and medication (Moderate/Severe TR, Moderate/Severe MR, LVEF, LVEDd, Beta-blocker). Abbreviations: COPD, Chronic obstructive pulmonary disease; CI, confidence interval; BP, blood pressure; Hb, Hemoglobin; BNP, Brain natriuretic peptide; TR, Tricuspid regurgitation; MR, Mitral regurgitation; LVEF, Left ventricle ejection fraction; LVEDd, Left ventricle end-diastolic diameter. After a subgroup analysis stratified according to PH probability, in the low PH probability subgroup, COPD or chronic bronchitis did not affect the survival rate (HR = 1.350, 95% CI = 0.301–6.061; p = 0.695). In the subgroup with an intermediate or high PH probability (HR = 2.645, 95% CI = 1.477–4.737, p = 0.001), patients with COPD or chronic bronchitis had a lower survival rate than patients without COPD or chronic bronchitis (as presented in Table 5 and Figure 2). Table 5.Association of comorbid COPD or chronic bronchitis with the prognosis subgroup analysis by PH probability.Cardiac deathGroupHazard ratio95% CI p PH probability LowWithout COPD or chronic bronchitisReference 0.695With COPD or chronic bronchitis1.3500.301–6.061 Intermediate or highWithout COPD or chronic bronchitisReference 0.001With COPD or chronic bronchitis2.6451.477–4.737 Notes: Association of Comorbid COPD or chronic bronchitis with prognosis subgroup analysis by PH probability were analyzed using Cox regression models. p < 0.05 is considered statistically significant. Abbreviations: COPD, Chronic obstructive pulmonary disease; CI, confidence interval; PH, pulmonary hypertension. Association of comorbid COPD or chronic bronchitis with the prognosis subgroup analysis by PH probability. Notes: Association of Comorbid COPD or chronic bronchitis with prognosis subgroup analysis by PH probability were analyzed using Cox regression models. p < 0.05 is considered statistically significant. Abbreviations: COPD, Chronic obstructive pulmonary disease; CI, confidence interval; PH, pulmonary hypertension. The Kaplan-Meier analysis in the subgroup of PH probability. (A) In the low PH probability subgroup, COPD or chronic bronchitis did not affect the survival rate (p = 0.694). (B) In the subgroup of intermediate or high PH probability, patients with COPD or chronic bronchitis had a lower survival rate than patients without COPD or chronic bronchitis (p = 0.001). Discussion To the best of our knowledge, this study is the first to explore the effect of COPD or chronic bronchitis on cardiac mortality in patients with DCM. In this study, 305 DCM patients were selected for a retrospective analysis and divided into low-, intermediate- and high-probability PH groups. The results showed that the risk of cardiac death in patients with DCM was greater when DCM was combined with COPD or chronic bronchitis. After grouping according to PH, the aforementioned risk difference was mainly reflected in the intermediate- or high-probability PH group. The Kaplan–Meier survival curve revealed that COPD or chronic bronchitis significantly reduced the survival rate of DCM patients, and the difference was more obvious at longer survival times. We used Cox regression models to minimize the deviation caused by confounding factors, and the results were the same. We propose two hypotheses to explain the results. First, patients with COPD or chronic bronchitis had a greater risk of PH. Second, patients with COPD have lower utilization of beta-blockers. First, the occurrence of COPD is irreversible, characterized by airflow limitation and caused by harmful gases or particles entering the body [15]. Chronic bronchitis is a common chronic respiratory disease that is characterized by recurrent cough, expectoration or a chronic course with wheezing [16]. COPD generally develops from chronic bronchitis and emphysema with a progressive, incompletely reversible limitation of airflow caused by a mixture of small airway disease and gas exchange impairment through parenchymal destruction [5,17,18]. COPD and chronic bronchitis have long disease courses and easily relapse, making them difficult to cure; they are also associated with the long-term use of antibiotics, bronchodilators and other drugs, which can have major side effects. Most of the patients are elderly individuals whose physical function is reduced and whose body resistance is low. PH can be triggered by hyperinflation, airway obstruction and airway collapse in patients with advanced COPD [19]. However, PH is directly related to the prognosis of DCM patients, and the incidence of cardiac death is markedly greater in patients with DCM and PH than in DCM patients without PH [11]. The development of PH in DCM is a multistage process. Left ventricular dilatation in patients with DCM leads to left ventricular systolic or diastolic dysfunction, resulting in MR. Subsequently, due to the increase in left ventricle filling pressure and passive backwards transmission, the left atrial pressure shows a chronic increasing trend, thereby increasing the pressure of the pulmonary veins and pulmonary arteries. As PH progresses, pulmonary endothelial dysfunction leads to obvious vasoconstriction and irreversible remodelling of pulmonary vessels, resulting in right ventricular deposition and hypertrophy. Because the right ventricle is more sensitive to long-term pressure overload, over time, the right side of the heart may be irreversibly damaged, eventually leading to heart failure. Due to the gradual expansion of the heart, reduced ventricular systolic function, and arrhythmia, DCM patients are often hospitalized repeatedly for heart failure. Some patients also have PH and haemodynamic changes as the disease progresses, resulting in right ventricular remodelling, causing heart failure and evolving to the final stage. Regarding the second explanation, with the continuous advancement of medical science, the benefits of pharmacological and nonpharmacological treatments for patients with DCM combined with COPD have become more obvious [20]. Beta-blockers have efficacy against some cardiovascular diseases. They are considered conventional drugs for the treatment of heart failure and can reduce pulmonary artery pressure. CVDs often coexist with pulmonary diseases [20], especially COPD. Due to concerns about adverse reactions such as the contraction of bronchial smooth muscle, especially in patients with advanced chronic COPD, beta-blockers have not been widely used in COPD patients [21,22]. Our study revealed a significant disparity in beta-blocker use, with lower rates in the COPD and chronic bronchitis groups, as shown in Table 2. This result is concerning because a higher heart rate is independently associated with greater mortality in both COPD and heart failure patients [23,24]. Notably, most of the data were obtained from populations enrolled more than a decade ago, when the importance of neurohormonal inhibition of the sympathetic nervous system in heart failure was less recognized. Therefore, our findings underscore the ongoing challenge of appropriately treating patients with DCM with COPD, which warrants greater attention from the cardiology community. Our study showed that patients with DCM combined with COPD or chronic bronchitis had a greater risk of cardiac death. After stratification by PH, a greater risk of cardiac death was observed mainly in the intermediate- or high-probability PH group, while no significant difference was noted in the low-PH probability group. According to the 2022 European Guidelines for Pulmonary Hypertension [25], in symptomatic patients with an intermediate or high echocardiographic probability of PH, further testing may be necessary to further determine the likelihood of PH and develop management strategies. However, although right heart catheterization (RHC) is the gold standard for PH diagnosis, it is relatively complicated, expensive, and invasive and is associated with a number of complications [26]. Therefore, most patients do not choose further diagnosis, resulting in insufficient management of PH during the follow-up period. As we mentioned earlier, the development of PH is a multistage process in the course of DCM. COPD or chronic bronchitis can affect the occurrence and progression of PH. Therefore, in the intermediate- or high-probability PH group, COPD or chronic bronchitis can accelerate the progression of PH, which is significantly related to the survival rate of patients with PH. Similarly, since PH is directly related to the prognosis of DCM patients, the prognosis is likely affected by COPD or chronic bronchitis, causing this difference in risk. This study has several limitations. First, many changes may have been made in heart failure and COPD treatment after discharge. We do not have specific data on the treatment that the patients received or on changes in pulmonary artery pressure during this time period. Second, as this study was retrospective and not all patients underwent pulmonary function tests during hospitalization, we were unable to assess the severity of COPD. Third, we did not perform RHC for PH diagnosis. Although RHC is an invasive and expensive examination, as the gold standard for the diagnosis of PH, it is undoubtedly more accurate for the determination of parameters related to PH. Fourth, the sample size was small, and bias may exist in the results of the subgroup analysis. Moreover, we included only patients with relatively complete baseline information and available follow-up data, indicating selection bias in the study population, which somewhat affected the validity of the statistical analysis. Multicentre, large-sample studies are needed to confirm our results. Conclusions Comorbid COPD or chronic bronchitis was associated with an increased incidence of cardiac death in DCM patients. After grouping by PH, the risk difference was mainly derived from the intermediate- or high-probability PH group. Our findings underscore the ongoing challenge of appropriately treating patients with DCM along with COPD, and in patients with an intermediate or high echocardiographic probability of PH, RHC is necessary for the further diagnosis of PH and development of management strategies. Funding Statement This work was supported by Incubation of Innovative Program of First Clinical Medical College of Guangzhou University of Chinese Medicine [2018XXDT01]. Authors contributions JL conceived and designed the study. RY and CL collectedthe data. PL, ZH, and BZ performed statistical analyses. GL and YZ wrote the manuscript. GZ supervised the study andapproved the final manuscript. All authors have contributedto the manuscript and approved the submitted version. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.